Literature DB >> 25316831

Oversight role of the Independent Monitoring Board of the Global Polio Eradication Initiative.

Paul D Rutter1, Liam J Donaldson1.   

Abstract

The Global Polio Eradication Initiative (GPEI) established its Independent Monitoring Board (IMB) in 2010 to monitor and guide its progress toward stopping polio transmission globally. The concept of an IMB is innovative, with no clear analogue in the history of the GPEI or in any other global health program. The IMB meets with senior program officials every 3-6 months. Its reports provide analysis and recommendations about individual polio-affected countries. The IMB also examines issues affecting the global program as a whole. Its areas of focus have included escalating the level of priority afforded to polio eradication (particularly by recommending a World Health Assembly resolution to declare polio eradication a programmatic emergency, which was enacted in May 2012), placing greater emphasis on people factors in the delivery of the program, encouraging innovation, strengthening focus on the small number of so-called sanctuaries where polio persists, and continuous quality improvement to reach every missed child with vaccination. The IMB's true independence from the agencies and countries delivering the program has enabled it to raise difficult issues that others cannot. Other global health programs might benefit from establishing similar independent monitoring mechanisms.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  monitoring; polio eradication; program governance

Mesh:

Substances:

Year:  2014        PMID: 25316831     DOI: 10.1093/infdis/jiu181

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016.

Authors:  Gavin B Grant; Balcha G Masresha; William J Moss; Mick N Mulders; Paul A Rota; Saad B Omer; Abigail Shefer; Jennifer L Kriss; Matt Hanson; David N Durrheim; Robert Linkins; James L Goodson
Journal:  Vaccine       Date:  2019-03-20       Impact factor: 3.641

2.  Transition Planning For After Polio Eradication.

Authors:  Paul D Rutter; Alan R Hinman; Lea Hegg; Dennis King; Stephen Sosler; Virginia Swezy; Ann-Lee Hussey; Stephen L Cochi
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

3.  Monitoring Results in Routine Immunization: Development of Routine Immunization Dashboard in Selected African Countries in the Context of the Polio Eradication Endgame Strategic Plan.

Authors:  Alain Poy; Maya M V X van den Ent; Stephen Sosler; Alan R Hinman; Sidney Brown; Samir Sodha; Daniel C Ehlman; Aaron S Wallace; Richard Mihigo
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

4.  A multi-pronged scoping review approach to understanding the evolving implementation of the Smallpox and Polio eradication programs: what can other Global Health initiatives learn?

Authors:  Meike Schleiff; Adetoun Olateju; Ellie Decker; Abigail H Neel; Rasheedat Oke; Michael A Peters; Aditi Rao; Olakunle Alonge
Journal:  BMC Public Health       Date:  2020-12-18       Impact factor: 3.295

5.  Innovations in vaccine delivery: increasing access, coverage, and equity and lessons learnt from measles and rubella elimination.

Authors:  James L Goodson; Paul A Rota
Journal:  Drug Deliv Transl Res       Date:  2022-02-24       Impact factor: 5.671

6.  Role of Serial Polio Seroprevalence Studies in Guiding Implementation of the Polio Eradication Initiative in Kano, Nigeria: 2011-2014.

Authors:  Kehinde TemilolaOluwa Craig; Harish Verma; Zubairu Iliyasu; Pascal Mkanda; Kebba Touray; Ticha Johnson; Abdullahi Walla; Richard Banda; Sisay G Tegegne; Yared G Yehualashet; Bashir Abba; Amina Ahmad-Shehu; Marina Takane; Roland W Sutter; Peter Nsubuga; Ado J G Muhammad; Rui G Vaz
Journal:  J Infect Dis       Date:  2016-02-09       Impact factor: 5.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.